Psychiatry and Neurology, Neurology · New Orleans, LA
NPI
1336246107
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
2820 Napoleon Ave, Suite 700
New Orleans, LA, 70115
Phone (504) 412-1517
Groups this clinician bills Medicare through
Medicare paid, 2024
$14K
160 services
Medicare patients, 2024
62
Average age 56
Drug cost, 2024
$6.9M
3,462 prescriptions
Company payments, 2025
$3,120
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jesus F Lovera was code 99215 (office e&m - established), 78 times for 38 patients. In total Jesus F Lovera billed 160 services in 18 codes, and Medicare paid $14K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-10-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 78 | 38 | $118.95 | $9,278 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 18 | 12 | $24.75 | $445 |
| 99214 Office E&M - Established | Office | 15 | 12 | $80.73 | $1,211 |
By year: 2022 $14K for 161 services; 2023 $13K for 165 services; 2024 $14K for 160 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jesus F Lovera prescribed most often to Medicare patients was Gabapentin, with 235 prescriptions and refills. In total Jesus F Lovera wrote 3,462 Medicare prescriptions that cost $6.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 235 | 271 | 42 | $4,731 |
| Baclofen Generic | 210 | 305 | 41 | $3,718 |
| Kesimpta Pen Ofatumumab | 199 | 199 | 21 | $1.8M |
| Dimethyl Fumarate Generic | 119 | 121 | 15 | $61K |
| Tizanidine Hcl Generic | 118 | 160 | 25 | $1,839 |
| Dalfampridine Er Dalfampridine | 114 | 148 | 18 | $78K |
| Pregabalin Generic | 77 | 86 | 15 | $1,389 |
| Tramadol Hcl Generic | 75 | 75 | Under 11 | $2,768 |
| Teriflunomide Generic | 70 | 70 | Under 11 | $3,447 |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 63 | 63 | Under 11 | $1,937 |
| Prednisone Generic | 61 | 78 | 21 | $714 |
| Escitalopram Oxalate Generic | 58 | 84 | 11 | $434 |
| Tysabri Natalizumab | 55 | 55 | Under 11 | $448K |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | 53 | 53 | Under 11 | $512K |
| Glatiramer Acetate Generic | 52 | 59 | Under 11 | $112K |
Brand drugs: 804 claims; generic drugs: 2,647 claims; opioid claims: 163.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jesus F Lovera $3,120 ($3,120 in general payments such as food, travel and fees) from 28 companies. The largest payer was Abbvie Inc. with $481.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 29 | $481 |
| Amgen Inc. AMGN | 13 | $391 |
| TG Therapeutics, Inc. TGTX | 9 | $297 |
| Biogen, Inc. BIIB | 10 | $278 |
| Novartis Pharmaceuticals Corporation NVS | 13 | $270 |
| Vanda Pharmaceuticals Inc. VNDA | 4 | $228 |
| UCB, Inc. UCB.BR | 7 | $186 |
| Genzyme Corporation SNY | 3 | $160 |
| Cycle Pharmaceuticals Inc | 3 | $89 |
| Eisai Inc. 4523.T | 4 | $81.48 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.